Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01)

This study is comparing cryoablation (a technique that uses extreme cold to destroy tumors) combined with lenvatinib plus tislelizumab (targeted therapy + immunotherapy) against standard FOLFOX chemotherapy in patients with advanced bile duct cancer (intrahepatic cholangiocarcinoma) that has not responded to one prior treatment. **You may be eligible if...** - You are 18 or older - You have confirmed unresectable or metastatic intrahepatic cholangiocarcinoma - Your cancer has progressed or was intolerable on 1 prior systemic treatment - You have at least one measurable tumor on imaging - Your general health score (ECOG) is 2 or below and life expectancy is at least 12 weeks **You may NOT be eligible if...** - You have clinically significant heart disease or had significant GI bleeding in the past 4 weeks - You had a stroke, deep vein thrombosis, or pulmonary embolism in the past 6 months - You previously received cryoablation, lenvatinib, or other targeted therapies - You had radiation or other ablation treatment within 4 weeks of study start Talk to your doctor to see if this trial is right for you.